South Africa’s Aspen sells menopause treatment rights for $220 million but keeps 10-year European supply deal
South African pharmaceutical company Aspen Pharmacare has agreed to sell the European rights to its women’s health product Ovestin to Ennogen Healthcare International for €197 million, equivalent to approximately $220 million.
By Ayodeji AdegboyegaSouth Africa
AI summary
Sign in to read the summary
Aspen chief executive Stephen Saad has prioritised asset sales and share buybacks as the South African drugmaker reshapes its international portfolio. [Aspen Pharmacare]
Follow the story
About this article
- Length
- 23 words · 1 min read
- Published
- November 3, 2026
- Byline
- Ayodeji Adegboyega
- Source
- Business Insider